Actiphage

PBD Biotech is one of the finalists selected to participate in the 42plus1 pitch event at DxPx EU in Munich, Germany on the 5th October 2023. This follows our participation in DxPx US.

The Inv€$tival Showcase in Old Billingsgate, London, is part of Europe’s biggest healthcare investment week. It will feature Actiphage TB, a groundbreaking diagnostic for tuberculosis.

PBD Biotech, developers of Actiphage® TB, a ground-breaking phage-based diagnostic for laboratory tuberculosis testing, has today announced it has secured the grant of a US patent for its diagnostic kit.

Actiphage TB is to enter its third clinical trial, which is aimed at validating its utility as a tuberculosis diagnostic. The phage-based diagnostic has potential for detecting TB progression.

We embrace the World TB day theme 'Yes! We Can End TB' with an educational webinar event on new diagnostic tests that are urgently needed to screen LTBI and determine who will progress to active TB disease.

Actiphage is the only test in development for subclinical tuberculosis that directly detects mycobacteria in the blood, it has been revealed by the TAG pipeline report

A clinical trial of Actiphage, a promising new diagnostic for tuberculosis infection, has shown for the first time that live bacteria can be detected in the blood of people with incipient TB infection.